Prosensa Holding NV
(NASDAQ : RNA)

( )
RNA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading RNA News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.31%165.221.3%$782.35m
GILDGilead Sciences, Inc.
-0.06%67.061.0%$564.12m
INCYIncyte Corporation
0.02%139.514.3%$556.22m
CELGCelgene Corporation
0.00%124.431.1%$495.09m
BIIBBiogen Inc.
0.00%274.111.3%$438.70m
REGNRegeneron Pharmaceuticals, Inc.
0.14%383.102.1%$349.89m
KITEKite Pharma, Inc.
0.00%78.6117.5%$217.46m
ALXNAlexion Pharmaceuticals, Inc.
0.00%118.531.6%$201.95m
TSROTESARO, Inc.
0.00%154.9015.6%$193.40m
ILMNIllumina, Inc.
-0.47%170.003.4%$168.21m
VRTXVertex Pharmaceuticals Incorporated
19.55%107.202.0%$160.27m
ESPREsperion Therapeutics, Inc.
1.96%36.3617.7%$152.95m
CLVSClovis Oncology, Inc.
0.00%67.0617.2%$140.22m
AUPHAurinia Pharmaceuticals Inc.
1.05%7.248.0%$131.89m
EXELExelixis, Inc.
0.00%21.285.7%$104.55m

Company Profile

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.